Noroxymorphone
Noroxymorphone is an opioid which is both a metabolite of oxymorphone and oxycodone and is manufactured specifically as an intermediate in the production of narcotic antagonists such as naltrexone and others. It is a potent agonist of the μ-opioid receptor, but is poorly able to cross the blood-brain-barrier into the central nervous system, and for this reason, has only minimal analgesic activity.

In the United States, noroxymorphone is controlled as a Schedule II Narcotic controlled substance with an ACSCN of 9637 and in 2014 the DEA set annual aggregate manufacturing quotas of 17 500 kilogrammes for conversion and 1262.5 kg for sale. In other countries, it may be similarly controlled, controlled at a lower level, or regulated in another way.
Q427523
opioid
Concept
Q407595
metabolite
Concept
Q423380
oxymorphone
Concept
Q407535
oxycodone
Concept
Q427523
narcotic antagonists
Concept
Q409587
naltrexone
Concept
Q389934
agonist
Concept
Q14911924
μ-opioid receptor
Concept
Q221694
blood-brain-barrier
Concept
Q47273
central nervous system
Concept
Q173235
analgesic
Concept
Q928770
Schedule II
PER
Q25102255
Noroxymorphone
UNK
9637-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
9637
DATE
2014-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
2014
DATE
1262-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
1262
DATE
+1262.5^^http://www.w3.org/2001/XMLSchema#decimal
1262.5
NUMBER
subject has role
subject has role
instance of
instance of